Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma?

We discuss all that and more on a special live (to tape) episode “The Readout LOUD,” STAT’s biotech podcast. In front of a studio audience in Boston, we talk about the first glimpse at how genome editing affects actual humans and the disappointment it brought. Then we take a look at how 2018 has panned out for some of biotech’s hot-button issues, including buyouts, IPOs, and President Trump’s effect on drug prices. We also dive into former Celgene CEO Bob Hugin’s effort to win a Senate race in New Jersey at a time when his industry is widely disliked. And then we embark upon live lightning round, answering questions from members of the audience.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy